Crestpoint Capital Management Has Lifted Holding in Fnf Group (FNF) by $397,800; Gamble Jones Investment Counsel Cut Its Abbott Labs (ABT) Holding by $2.12 Million as Share Value Rose

April 22, 2018 - By Vivian Currie

Abbott Laboratories (NYSE:ABT) Logo

Crestpoint Capital Management Llc increased its stake in Fnf Group (FNF) by 68.92% based on its latest 2017Q4 regulatory filing with the SEC. Crestpoint Capital Management Llc bought 10,200 shares as the company’s stock rose 4.07% while stock markets declined. The institutional investor held 25,000 shares of the finance company at the end of 2017Q4, valued at $981,000, up from 14,800 at the end of the previous reported quarter. Crestpoint Capital Management Llc who had been investing in Fnf Group for a number of months, seems to be bullish on the $10.44 billion market cap company. The stock increased 0.55% or $0.21 during the last trading session, reaching $38.05. About 1.14 million shares traded. Fidelity National Financial, Inc. (NYSE:FNF) has risen 46.00% since April 22, 2017 and is uptrending. It has outperformed by 34.45% the S&P500.

Gamble Jones Investment Counsel decreased its stake in Abbott Labs (ABT) by 11.62% based on its latest 2017Q4 regulatory filing with the SEC. Gamble Jones Investment Counsel sold 37,129 shares as the company’s stock rose 5.88% while stock markets declined. The institutional investor held 282,445 shares of the major pharmaceuticals company at the end of 2017Q4, valued at $16.12 million, down from 319,574 at the end of the previous reported quarter. Gamble Jones Investment Counsel who had been investing in Abbott Labs for a number of months, seems to be less bullish one the $103.37B market cap company. The stock decreased 1.15% or $0.69 during the last trading session, reaching $59.19. About 5.87 million shares traded. Abbott Laboratories (NYSE:ABT) has risen 34.85% since April 22, 2017 and is uptrending. It has outperformed by 23.30% the S&P500.

Crestpoint Capital Management Llc, which manages about $225.04 million and $180.17 million US Long portfolio, decreased its stake in Dowdupont Inc by 15,900 shares to 18,456 shares, valued at $1.31 million in 2017Q4, according to the filing. It also reduced its holding in Apple (NASDAQ:AAPL) by 7,400 shares in the quarter, leaving it with 22,000 shares, and cut its stake in At&T Inc (NYSE:T).

Investors sentiment increased to 1.44 in 2017 Q4. Its up 0.23, from 1.21 in 2017Q3. It improved, as 40 investors sold FNF shares while 87 reduced holdings. 53 funds opened positions while 130 raised stakes. 219.60 million shares or 1.84% more from 215.64 million shares in 2017Q3 were reported. Advisory Service Ltd Limited Liability Company has invested 0.05% in Fidelity National Financial, Inc. (NYSE:FNF). Bessemer Gru Inc holds 24,571 shares. Moreover, Maltese Ltd Liability has 0.44% invested in Fidelity National Financial, Inc. (NYSE:FNF). Fund Mngmt Sa holds 23,100 shares. Gateway Invest Advisers Ltd Liability Company owns 155,481 shares. D E Shaw Company reported 2.21M shares stake. 512,486 are owned by Asset Management One Com Limited. Valley National Advisers Inc owns 49 shares or 0% of their US portfolio. Kbc Grp Inc Nv has 308,710 shares. State Board Of Administration Of Florida Retirement reported 453,371 shares stake. Brinker Capital reported 0.01% of its portfolio in Fidelity National Financial, Inc. (NYSE:FNF). 36,679 are held by Us National Bank & Trust De. Lionstone Ltd Limited Liability Company invested 6.82% in Fidelity National Financial, Inc. (NYSE:FNF). Hudock Cap Group Ltd Liability Corp invested in 0.01% or 445 shares. Great West Life Assurance Com Can, a Manitoba – Canada-based fund reported 216,485 shares.

Among 8 analysts covering Fidelity National Financial (NYSE:FNF), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Fidelity National Financial had 26 analyst reports since August 3, 2015 according to SRatingsIntel. The stock has “Buy” rating by SunTrust on Friday, January 26. The stock of Fidelity National Financial, Inc. (NYSE:FNF) has “Market Perform” rating given on Monday, July 18 by Wood. Barclays Capital maintained it with “Overweight” rating and $46 target in Friday, February 12 report. The rating was maintained by Piper Jaffray on Wednesday, January 31 with “Buy”. On Friday, October 27 the stock rating was maintained by Barclays Capital with “Overweight”. As per Friday, May 5, the company rating was maintained by Monness Crespi. The stock of Fidelity National Financial, Inc. (NYSE:FNF) has “Buy” rating given on Thursday, October 19 by SunTrust. The rating was maintained by Piper Jaffray on Monday, December 18 with “Buy”. The firm has “Hold” rating by Keefe Bruyette & Woods given on Thursday, December 21. The rating was maintained by Piper Jaffray on Tuesday, September 12 with “Buy”.

Among 25 analysts covering Abbott Laboratories (NYSE:ABT), 18 have Buy rating, 0 Sell and 7 Hold. Therefore 72% are positive. Abbott Laboratories had 106 analyst reports since July 24, 2015 according to SRatingsIntel. RBC Capital Markets maintained Abbott Laboratories (NYSE:ABT) on Thursday, July 23 with “Outperform” rating. As per Tuesday, September 13, the company rating was maintained by Jefferies. The stock of Abbott Laboratories (NYSE:ABT) has “Buy” rating given on Tuesday, June 21 by Edward Jones. The rating was maintained by Jefferies with “Buy” on Tuesday, October 10. The rating was upgraded by BMO Capital Markets on Tuesday, December 12 to “Outperform”. Stifel Nicolaus maintained the shares of ABT in report on Friday, September 22 with “Buy” rating. The rating was maintained by Jefferies on Wednesday, January 24 with “Buy”. The firm earned “Overweight” rating on Wednesday, October 7 by Barclays Capital. The firm has “Buy” rating given on Thursday, January 25 by William Blair. The rating was downgraded by Northland Capital on Thursday, September 28 to “Hold”.

Since October 23, 2017, it had 1 insider buy, and 18 insider sales for $23.52 million activity. $2.69 million worth of Abbott Laboratories (NYSE:ABT) was sold by Ford Robert B on Tuesday, January 30. MANNING JOSEPH J sold $84,344 worth of Abbott Laboratories (NYSE:ABT) on Wednesday, February 28. Blaser Brian J sold $1.73 million worth of Abbott Laboratories (NYSE:ABT) on Wednesday, January 31. The insider Funck Robert E sold 1,220 shares worth $71,970. On Wednesday, February 28 BIRD ROGER sold $96,728 worth of Abbott Laboratories (NYSE:ABT) or 1,645 shares. $53,369 worth of Abbott Laboratories (NYSE:ABT) shares were sold by Salvadori Daniel Gesua Sive.

Investors sentiment increased to 0.91 in 2017 Q4. Its up 0.04, from 0.87 in 2017Q3. It is positive, as 52 investors sold ABT shares while 558 reduced holdings. 123 funds opened positions while 430 raised stakes. 1.22 billion shares or 0.64% more from 1.21 billion shares in 2017Q3 were reported. Cape Cod Five Cents Commercial Bank has 56,800 shares for 0.49% of their portfolio. Moreover, Gam Ag has 0.02% invested in Abbott Laboratories (NYSE:ABT). Beck Mack Oliver accumulated 1.40M shares or 2.63% of the stock. Stralem And reported 2.65% stake. Sawgrass Asset Management Ltd Liability Co holds 0.79% or 303,384 shares. Moreover, Canandaigua Bankshares & has 0.37% invested in Abbott Laboratories (NYSE:ABT). Moreover, Eastern Bancorporation has 0.06% invested in Abbott Laboratories (NYSE:ABT). Boston And Mgmt invested in 1.67% or 58,502 shares. Brookmont Cap Mngmt, Texas-based fund reported 110,995 shares. Osterweis Cap Mngmt holds 0.01% or 3,700 shares in its portfolio. M Holdings Inc reported 10,461 shares stake. Mountain Pacific Invest Advisers Id stated it has 33,701 shares or 0.2% of all its holdings. Virtus Inv Advisers Inc has invested 0.2% of its portfolio in Abbott Laboratories (NYSE:ABT). Warren Averett Asset Llc invested in 13,092 shares or 0.11% of the stock. Mengis Capital holds 0.23% of its portfolio in Abbott Laboratories (NYSE:ABT) for 6,629 shares.

Abbott Laboratories (NYSE:ABT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts